AGILeBiotics will attend the Bio-Europe Meeting in Berlin (Germany) from 6-8 November, 2017

POSTED ON 3.10.2017

AGILeBiotics was attending the BioPharm America Meeting in Boston (MA, US) from 25-27 September, 2017

POSTED ON 3.10.2017

Dr. Andreas A. Bastian (left) and Dr. Maria Bastian (right)

AGILeBiotics was featured by Campus Groningen in a short movie

POSTED ON 24.08.2017

Please click here to watch a short movie about AGILeBiotics’ activities

We are proud to introduce the new CSO of AGILeBiotics

POSTED ON 1.06.2017

Starting from June 1, 2017, Dr. Maria Bastian is appointed as Chief Science Officer at AGILeBiotics.

AGILEBIOTICS is featured in RUG’s newsletter

posted on 16.05.2017

The Newsletter from Research & Valorisation of the University of Groningen (RUG) published an article about AGILeBiotics’ vision and mission.

AGILeBiotics is member of the Life Cooperative

posted on 15.05.2017

Life Science and Medical Technology SMEs in the Northern part of the Netherlands are uniting in the Healthy Ageing Business Cooperative in order to influence policy markers of regional governments and institutions.

Healthy Ageing Network


AGILeBiotics joins the Health-i-Care program

posted on 10.04.2017

AGILeBiotics entered successfully the Health-i-Care program (INTERREG) starting a collaboration with the University Medical Center Groningen (UMCG) and Hospitals in Germany (Muenster and Oldenburg). Health-i-Care is focusing on the development of innovative products and technologies to protect the society from infections caused by resistant microorganisms and to limit the spread of multidrug resistant bacteria.


Health i Care


AGILeBiotics started a collaboration with Syncom BV

posted on 1.03.2017

AGILeBiotics has started a collaboration with Syncom BV, a CRO company in Groningen, to develop novel antibiotic candidates against life-threatening infections. Together with Syncom’s experience synthetic chemists AGILebiotics is generating libraries of antibiotic candidates based on natural products for pre-clinical and clinical development.


AGILeBiotics receives a pre-seed investment

posted on 1.03.2017

AGILeBiotics received a pre-seed investment from three local investors, i.e. RUG Houdstermaatschappij BV, Stichting Ir G.J. Smid Fonds BV, and Hanzepoort BV. With this financial support, AGILeBiotics has started its drug discovery and development program, and envisions to advance first antibiotic candidates into late pre-clinical development in 2018.




AGILEBIOTICS receives the Take-off fase one grant from NWO

posted on 1.02.2017

AGILeBiotics’s team has been awarded with the Take-off face one grant (EUR 40.000) from the Netherlands Organisation for Scientific Research (NWO). Supported by Prof. Dr. Adriaan Minnaard and the Take-off grant, the team could perform essential feasibility studies and screen for funding opportunities.


Welkom bij het NWO